These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 23954144

  • 1. Options for metastatic colorectal cancer beyond the second line of treatment.
    Foubert F, Matysiak-Budnik T, Touchefeu Y.
    Dig Liver Dis; 2014 Feb; 46(2):105-12. PubMed ID: 23954144
    [Abstract] [Full Text] [Related]

  • 2. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
    Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P.
    Cancer Treat Rev; 2014 Jul; 40(6):701-15. PubMed ID: 24731471
    [Abstract] [Full Text] [Related]

  • 3. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L, Nagykálnai T.
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [Abstract] [Full Text] [Related]

  • 4. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N, Heinemann V.
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [Abstract] [Full Text] [Related]

  • 5. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P, Grande E, Polo E, Afonso R, Reina JJ, Jorge M, Campos JM, Martínez V, Angeles C, Montagut C.
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [Abstract] [Full Text] [Related]

  • 6. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY.
    Genet Mol Res; 2011 Oct 03; 10(4):3002-12. PubMed ID: 21968808
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct 03; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
    Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V.
    Int J Cancer; 2013 Jan 01; 132(1):236-45. PubMed ID: 22644776
    [Abstract] [Full Text] [Related]

  • 9. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY, Haaland BA, de Lima Lopes G.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):231-8. PubMed ID: 22699811
    [Abstract] [Full Text] [Related]

  • 10. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC.
    Anticancer Drugs; 2012 Jul 01; 23(6):666-73. PubMed ID: 22441566
    [Abstract] [Full Text] [Related]

  • 11. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 01; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 01; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Pohlmann PR, Mernaugh RL, Goff LW.
    N Engl J Med; 2009 May 14; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
    Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW.
    Clin Colorectal Cancer; 2014 Sep 14; 13(3):145-55. PubMed ID: 25209093
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Progress in the development of novel treatments for colorectal cancer.
    Hoff PM, Pazdur R.
    Oncology (Williston Park); 2004 May 14; 18(6):705-8. PubMed ID: 15214591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.